Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma

15 Nov 2011

Abstract excerpt

Renal cell carcinoma (RCC) is an angiogenesis-dependent and hypoxia-driven malignancy. As a result, there has been an increased interest in the use of antiangiogenic agents for the management of RCC in patients. However, the activity of tumor-vascular disrupting agents (tumor-VDA) has not been extensively examined against RCC. In this study, we investigated the therapeutic efficacy of the tumor-VDA ASA404 (DMXAA,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Renal and related cancers
Share to Renal and Vascular Pathologies
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22084164
DOI: 10.1158/1535-7163.mct-11-0748

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Vascular Disruption in Combination with mTOR Inhibition in Renal Cell CarcinomaPMID 22084164Read ↗

Atractylenolide I inhibits angiogenesis and reverses sunitinib resistance in clear cell renal cell carcinoma through ATP6V0D2-mediated autophagic degradation of EPAS1/HIF2αSemantic proximity Read ↗

Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.Semantic proximity Read ↗

Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.Semantic proximity Read ↗

Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo ?Semantic proximity Read ↗

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenibSemantic proximity Read ↗

Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.Semantic proximity Read ↗

Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.Semantic proximity Read ↗

Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice.Semantic proximity Read ↗

Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.